Indication
Treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
Medicine details
- Medicine name:
- seladelpar (Livdelzi)
- SMC ID:
- SMC2835
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Publication due date:
- 08 December 2025
- SMC meeting date:
- 04 November 2025
- Patient group submission deadline:
- TBC